Dipyridamole: Advanced Antiplatelet Therapy for Thrombosis Prevention
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.89 | $53.35 (0%) | 🛒 Add to cart |
| 90 | $0.82 | $80.03 $73.49 (8%) | 🛒 Add to cart |
| 180 | $0.76 | $160.06 $136.90 (14%) | 🛒 Add to cart |
| 270 | $0.73 | $240.09 $196.30 (18%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $320.11 $258.71 (19%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.48 | $43.29 (0%) | 🛒 Add to cart |
| 120 | $0.43 | $57.71 $51.34 (11%) | 🛒 Add to cart |
| 180 | $0.38 | $86.57 $68.45 (21%) | 🛒 Add to cart |
| 270 | $0.34 | $129.86 $91.61 (29%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $173.14 $118.78 (31%) | 🛒 Add to cart |
Synonyms
| |||
Dipyridamole is a platelet adhesion inhibitor and vasodilator used primarily in the prevention of thromboembolic events, particularly in patients with cardiac valve replacements or a history of stroke. It functions by increasing cyclic adenosine monophosphate (cAMP) levels in platelets and enhancing prostacyclin-induced inhibition of platelet aggregation. This agent is often utilized in combination with other anticoagulants, such as warfarin, to provide a synergistic effect in maintaining vascular patency and reducing clot formation. Its unique mechanism offers a valuable option in comprehensive antithrombotic regimens.
Features
- Chemical name: 2,2’,2’’,2’’’-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol
- Molecular formula: C₂₄H₄₀N₈O₄
- Available in oral tablet formulations, commonly 25 mg, 50 mg, and 75 mg strengths
- Also available in combination with aspirin for enhanced antiplatelet efficacy
- Half-life: approximately 10–12 hours
- Peak plasma concentration reached within 2–3 hours post-administration
- Metabolized hepatically via glucuronidation and excreted primarily in bile
Benefits
- Reduces the risk of stroke and systemic embolism in select patient populations
- Provides adjunctive antiplatelet activity when used in combination with other anticoagulants
- Exhibits vasodilatory properties which may support coronary blood flow
- Lower incidence of hemorrhagic complications compared to some stronger anticoagulants when used as monotherapy
- Suitable for long-term maintenance therapy in chronic conditions
- May be used in patients with certain prosthetic heart valves to prevent thrombus formation
Common use
Dipyridamole is indicated for the prevention of postoperative thromboembolic complications associated with prosthetic heart valves, typically in combination with warfarin. It is also used in secondary prevention of ischemic stroke and transient ischemic attacks (TIAs), often alongside aspirin. Off-label applications include use in certain coronary artery disease protocols and as an alternative for patients intolerant to other antiplatelet agents.
Dosage and direction
The typical adult dosage for dipyridamole is 75–100 mg taken orally four times daily. When used in combination with warfarin for prosthetic heart valve patients, the dosage is generally adjusted based on prothrombin time/INR monitoring. For stroke prevention, a common regimen is 200 mg twice daily in extended-release form combined with aspirin. Administration should occur on an empty stomach, at least one hour before or two hours after meals, to optimize absorption. Dosage adjustments may be necessary in patients with hepatic impairment.
Precautions
Patients should be monitored for signs of bleeding or unusual bruising. Use with caution in those with hypotension, as dipyridamole can cause vasodilation. Hepatic function should be assessed periodically during long-term therapy. It is not recommended in patients with severe coronary artery disease without careful cardiovascular monitoring due to the risk of coronary steal phenomenon. Caution is advised when administering to elderly patients, who may be more susceptible to adverse effects.
Contraindications
Hypersensitivity to dipyridamole or any component of the formulation. Should not be used in patients with active pathological bleeding, such as peptic ulcer disease or intracranial hemorrhage. Contraindicated in those with unstable angina or recent myocardial infarction unless closely monitored in a controlled setting.
Possible side effect
- Headache (most common, often dose-related)
- Dizziness or lightheadedness
- Gastrointestinal disturbances (nausea, vomiting, diarrhea, or abdominal pain)
- Flushing or feeling of warmth
- Hypotension or tachycardia
- Rash or pruritus
- Fatigue or weakness
- Exacerbation of symptoms in patients with coronary artery disease
Drug interaction
- Increased risk of bleeding when used with other antiplatelet agents, anticoagulants, or thrombolytics
- Adenosine: dipyridamole may potentiate its effects, increasing risk of bradycardia and hypotension
- Cholinesterase inhibitors: may be antagonized
- Hepatic enzyme inducers (e.g., rifampin) may reduce efficacy
- Antacids may decrease absorption; administer separately
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms may include severe hypotension, tachycardia, warmth or flushing, and dizziness. Management is primarily supportive, including maintaining blood pressure with fluids and vasopressors if necessary. There is no specific antidote; gastric lavage may be considered if ingestion was recent. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20–25°C or 68–77°F), in a tightly closed container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and to address any health concerns or before starting any new medication.
Reviews
Clinical studies and meta-analyses have demonstrated the efficacy of dipyridamole, particularly in combination with aspirin, for secondary stroke prevention. It is generally well-tolerated, though headache is a frequently reported side effect that often diminishes with continued use. Many experts regard it as a valuable option in specific patient populations where alternative antiplatelet therapies are contraindicated or poorly tolerated.